CACNA1C
ENSG00000151067
Target class
Ion channel
Chromosome
12
Approved drugs
21
Clinical candidates (approved and in development)
35
- Approved drugs
- 21
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 35
- Chemical probe available
- No
- Target name
- CACNA1C
- Gene name
- Calcium voltage-gated channel subunit alpha1 C
- Gene symbol
- CACNA1C
- Protein name
- Voltage-dependent L-type calcium channel subunit alpha-1C (Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle) (Voltage-gated calcium channel subunit alpha Cav1.2)
- Cav1.2
- CACH2
- CACN2
- TS
- LQT8
- CCHL1A1
- CACNL1A1
- CACNA1C-IT2
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 48
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 44.45
- Tissue specificity (Gini)
- 0.575
- Tissue specificity (tau)
- 0.852
- KEGG gene identifiers
- hsa:775
- Protein interaction confidence
- 0.850958
- Protein interaction partners
- 119
- R-HSA-400042
- R-HSA-419037
- R-HSA-422356
- R-HSA-5576892
- R-HSA-5576893
- End position
- 2697950
- Start position
- 1970772
- Chromosome
- 12
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cell membrane, sarcolemma
- Multi-pass membrane protein . Perikaryon . Postsynaptic density membrane . Cell projection, dendrite . Cell membrane, sarcolemma, T-tubule . Note=Colocalizes with ryanodine receptors in distinct clusters at the junctional membrane, where the sarcolemma and the sarcoplasmic reticulum are in close contact. The interaction between RRAD and CACNB2 promotes the expression of CACNA1C at the cell membrane. .
- Plasma membrane
- PubMed 11741969
- PubMed 12176756
- PubMed 12181424
- PubMed 15454078
- PubMed 15863612
- PubMed 16299511
- PubMed 17071743
- PubMed 17224476
- PubMed 20953164
- PubMed 24728418
- PubMed 26253506
- PubMed 27218670
- PubMed 29078335
- PubMed 29742403
- PubMed 7737988
- PubMed 8099908
- PubMed 8392192
- PubMed 9013606
- PubMed 9087614
- PubMed 9607315
- Tissue specificity (tau)
- 0.851667
- Expression inequality (Gini)
- 0.575064
Expression in transcripts per million
- Colon - Sigmoid
- 44.45
- Uterus
- 33.64
- Artery - Coronary
- 26.33
- Esophagus - Muscularis
- 24.9
- Artery - Tibial
- 23.21
Expression in transcripts per million
- Colon - Sigmoid44.45
- Uterus33.64
- Artery - Coronary26.33
- Esophagus - Muscularis24.9
- Artery - Tibial23.21
- Artery - Aorta23.03
- Esophagus - Gastroesophageal Junction19.16
- Bladder16.56
- Heart - Atrial Appendage11.04
- Colon - Transverse10.83
- Heart - Left Ventricle10.65
- Cervix - Endocervix10.57
- Prostate9.5
- Cervix - Ectocervix8.32
- Pituitary8.29
- Brain - Cerebellum7.97
- Lung7.06
- Brain - Cerebellar Hemisphere6.98
- Fallopian Tube6.48
- Brain - Cortex6.15
- Cells - Cultured fibroblasts5.71
- Brain - Frontal Cortex (BA9)5.61
- Vagina4.69
- Testis4.62
- Spleen4.35
And 29 more, listed on the interactive page.
- GO:0002520
- GO:0007204
- GO:0007507
- GO:0010881
- GO:0035115
- GO:0043010
- GO:0060402
- GO:0061337
- GO:0061577
- GO:0070588
- GO:0086002
- GO:0086012
- GO:0086045
- GO:0086064
- GO:0086091
- GO:0098911
- GO:0098912
- GO:0005737
- GO:0005886
- GO:0005891
- GO:0014069
- GO:0016020
- GO:1990454
- GO:0005245
- GO:0005515
- GO:0005516
- GO:0008331
- GO:0051393
- GO:0086007
- GO:0086056
increased mortality of heart failure patients
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased mortality of heart failure patients
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcefluid buildup in the legs
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: fluid buildup in the legs
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: dizziness
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceincreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased convulsions
- central nervous system
- cardiovascular
PubMed 28216264induction of seizures
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: induction of seizures
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedecreased/increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased/increased convulsions
- central nervous system
- cardiovascular
PubMed 28216264increased PR interval
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased PR interval
- central nervous system
- cardiovascular
PubMed 28216264effect on heart rate
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: effect on heart rate
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcehypotension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypotension
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcereflex tachycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: reflex tachycardia
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedecreased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased cardiac contractility
- central nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- central nervous system
- cardiovascular
PubMed 28216264constipation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: constipation
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedecreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood pressure
- central nervous system
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac contractility
- central nervous system
- cardiovascular
PubMed 28216264increased systolic blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased systolic blood pressure
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceincreases in peripheral vascular resistance
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increases in peripheral vascular resistance
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceincreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- central nervous system
- cardiovascular
PubMed 28216264arrhythmia
- Inhibition/Decrease/Downregulation: general
- Activation/Increase/Upregulation: general
Studies
- clinical: arrhythmia
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceheadache
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: headache
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceredness in the face
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: redness in the face
- cardiovascular system
- nervous system
- gastrointestinal
Evidence source
decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased blood pressure
Biological samples
- cardiovascular system
PubMed 23197038decreased PR interval
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased PR interval
Biological samples
- cardiovascular system
PubMed 23197038possible shortening of QT interval of ECG
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: possible shortening of QT interval of ECG
Biological samples
- cardiovascular system
PubMed 23197038vascular relaxation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: vascular relaxation
Biological samples
- cardiovascular system
PubMed 23197038
Related records
Trials (2,059)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
Drugs (44)
- Amlodipine Voltage-gated L-type calcium channel blocker
- Amlodipine benzoate Voltage-gated L-type calcium channel blocker
- Amlodipine besylate Voltage-gated L-type calcium channel blocker
- Amlodipine maleate Voltage-gated L-type calcium channel blocker
- Atagabalin Voltage-gated calcium channel modulator
- AZD1305 Voltage-gated L-type calcium channel blocker
- Azelnidipine Voltage-gated L-type calcium channel blocker
- Barnidipine Voltage-gated L-type calcium channel blocker
- Benidipine Voltage-gated L-type calcium channel blocker
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Cilnidipine Voltage-gated L-type calcium channel blocker
- Cinnarizine Voltage-gated L-type calcium channel blocker
- Clevidipine Voltage-gated L-type calcium channel blocker
- Diltiazem Voltage-gated L-type calcium channel blocker
- Diltiazem hydrochloride Voltage-gated L-type calcium channel blocker
- Diltiazem malate Voltage-gated L-type calcium channel blocker
- Dronedarone Voltage-gated L-type calcium channel blocker
- Dronedarone hydrochloride Voltage-gated L-type calcium channel blocker
- Elpetrigine Voltage-gated L-type calcium channel blocker